20.02.2013 Views

Drug Targeting Organ-Specific Strategies

Drug Targeting Organ-Specific Strategies

Drug Targeting Organ-Specific Strategies

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

350 13 Pharmacokinetic/Pharmacodynamic Modelling in <strong>Drug</strong> <strong>Targeting</strong><br />

13.3 Pharmacokinetic Models for <strong>Drug</strong> <strong>Targeting</strong><br />

In 1980, Stella and Himmelstein [5] introduced the principles of pharmacokinetic modelling<br />

into the field of pro-drugs and site-specific delivery. In 1986, Hunt et al. [6] extended the model<br />

of Stella and Himmelstein by taking into account a specific area where toxicity occurs.<br />

Their work may be considered as the frame of reference for later work in this area.<br />

13.3.1 Model of Stella and Himmelstein<br />

The model of Stella and Himmelstein [5], depicted in Figure 13.3, was originally derived for<br />

pro-drugs, and may be considered as a minimal model for evaluating the pharmacokinetics of<br />

pro-drugs and drug targeting systems. Since the drug–carrier conjugate (DC) and the active<br />

drug (D) are different entities, and since the model should be able to discriminate between<br />

the target site and non-target sites, a pharmacokinetic model for drug–carrier conjugates<br />

should include, at least, the following compartments (Figure 13.3):<br />

RC(DC)<br />

DC<br />

response (target)<br />

compartment<br />

VR(DR)<br />

DC<br />

central<br />

compartment<br />

VC(DR)<br />

CLC (DC)<br />

Vmax R<br />

Km R<br />

Vmax C<br />

Km C<br />

D<br />

response (target)<br />

compartment<br />

VR(D)<br />

CLCR(DC) CLCR(D)<br />

D<br />

central<br />

compartment<br />

VC(D)<br />

CLC (D)<br />

Figure 13.3. Model of Stella and Himmelstein, adapted from reference [5] (Section 13.3.1). The<br />

drug–carrier conjugate (DC) is administered at a rate R C(DC) into the central compartment of DC,<br />

which is characterized by a volume of distribution V C(DC). DC is transported with an intercompartmental<br />

clearance CL CR(DC) to and from the response (target) compartment with volume<br />

V R(DC), and is eliminated from the central compartment with a clearance CL C(DC). The active drug<br />

(D) is released from DC in the central and response compartments via saturable processes obeying<br />

Michaelis–Menten kinetics defined by Vmax and Km values. D is distributed over the volumes V C(D)<br />

and V R(D) of the central and response compartment, respectively. D is transported with an intercompartmental<br />

clearance CL CR(D) between the central compartment and response compartment, and<br />

is eliminated from the central compartment with a clearance CL C(D).

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!